Halozyme Therapeutics, Inc. earnings per share and revenue
On Nov 03, 2025, HALO reported earnings of 1.72 USD per share (EPS) for Q3 25, beating the estimate of 1.66 USD, resulting in a 3.56% surprise. Revenue reached 354.26 million, compared to an expected 346.72 million, with a 2.18% difference. The market reacted with a +2.79% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Holdings Inc. Common Stock
Report Date
Dec 22, 2025 For Q4 25
Estimate
-$0.57
Actual
-$0.73
Surprise
-25.95%
Outlook Therapeutics, Inc. Common Stock
Report Date
Dec 19, 2025 For Q4 25
Estimate
-$0.25
Actual
-$0.19
Surprise
+26.47%
Citius Oncology, Inc. Common Stock
Report Date
Dec 23, 2025 For Q4 25
Estimate
-$0.12
Actual
-$0.06
Surprise
+50.98%
FAQ
What were Halozyme Therapeutics, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Halozyme Therapeutics, Inc. reported EPS of $1.72, beating estimates by 3.56%, and revenue of $354.26M, 2.18% above expectations.
How did the market react to Halozyme Therapeutics, Inc.'s Q3 2025 earnings?
The stock price moved up 2.79%, changed from $66.20 before the earnings release to $68.05 the day after.
When is Halozyme Therapeutics, Inc. expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Halozyme Therapeutics, Inc.'s next earnings report?
Based on --
analysts, Halozyme Therapeutics, Inc. is expected to report EPS of -- and revenue of -- for Q-- --.